Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Glucodynia.

JPMA. The Journal of the Pakistan Medical Association·2025

Same author

Medical termination of unplanned pregnancies in women with diabetes.

JPMA. The Journal of the Pakistan Medical Association·2025

Same author

Gonadal guardianship-ergonomic endocrinology.

JPMA. The Journal of the Pakistan Medical Association..·2025

Same author

Socionutrition: The science of socionutrients.

JPMA. The Journal of the Pakistan Medical Association·2025

Same author

Somnometabolic Syndrome Revisited.

JPMA. The Journal of the Pakistan Medical Association·2024

Same author

The International Evidence-based Guidelines for the Assessment and Management of Polycystic Ovary Syndrome: An Exemplar of Person-centred Care.

TouchREVIEWS in endocrinology·2024

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Combination therapy in hypertension: An update.

Sanjay Kalra¹, Bharti Kalra, Navneet Agrawal

¹Dept of Endocrinology, Bharti Hospital, Karnal, India. brideknl@gmail.com.

Diabetology & Metabolic Syndrome

|June 26, 2010

Summary

Effective hypertension management requires combination therapy, not monotherapy, especially for patients with diabetes. Combining medications improves blood pressure control, reduces side effects, and enhances patient compliance for better cardiovascular outcomes.

Related Experiment Videos

Last Updated: Jun 12, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

Cardiology
Pharmacology

Background:

Hypertension control is crucial for reducing cardiovascular events, particularly in patients with comorbidities like diabetes mellitus.
Monotherapy is often insufficient for achieving target blood pressure in most hypertensive patients.
Multiple factors contribute to hypertension, suggesting combination therapy may be more effective than monotherapy.

Purpose of the Study:

To review the role and benefits of combination therapy in managing hypertension.
To discuss various antihypertensive drug classes and their combinations.
To highlight the importance of individualized treatment strategies based on comorbidities and special populations.

Main Methods:

Review of recent clinical trials and established antihypertensive drug classes.
Analysis of fixed-dose combinations versus sequential drug addition.
Discussion of drug classes including ARBs, diuretics, beta-blockers, calcium antagonists, and ACE inhibitors.

Main Results:

Combination therapy offers a more effective approach to blood pressure control compared to monotherapy.
Fixed-dose combinations provide convenience, potentially lower individual drug doses, reduce side effects, and improve compliance.
Diuretic-based combinations are common, and effective agents include thiazide diuretics, calcium channel blockers, and renin-angiotensin-aldosterone system blockers.

Conclusions:

Combination antihypertensive therapy is essential for optimal blood pressure control and reduction of cardiovascular endpoints.
Individualized combination regimens are necessary, considering comorbidities such as diabetes, chronic renal failure, heart failure, and specific populations like the elderly and pregnant women.
Future strategies should focus on tailored combination therapies for diverse patient profiles to maximize clinical benefits.